Gvs S.p.a · MIL:GVS

Gvs — Investor Presentation (September 2026)

16 slides from Gvs's investor presentation, Sep 24, 2026

  1. Slide 1: 2026-2028 Business Plan

    • 2026-2028 BUSINESS PLAN • September 24th, 2026

  2. Slide 2: FY 2026 Guidance Update

    FY 2026 Guidance Update

  3. Slide 3: FY 2026 Guidance Revised Upwards

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2026 Guidance Revised Upwards Revenues Mid-single-digit organic (excl. FX) revenues growth vs. FY 2025 Adjusted 50-100 bps of margin expansion vs. FY 2025 EB

  4. Slide 4: FY 2026 Revenue Growth by Division

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx FY 2026 Revenue Growth by Division FY 2026 Organic Revenues Division(1) Growth Drivers Growth vs. FY 2025 MedTech Low-single-digit Commercial synergies Transfus

  5. Slide 5: 2026-2028 Business Plan

    2026-2028 Business Plan

  6. Slide 6: 2026-2028: Harvesting the Investment Cycle

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 2026-2028: Harvesting the Investment Cycle The 2022-2025 investment cycle now turns into performance — organic revenue growth from commercial synergies, margin

  7. Slide 7: 2026-2028: Strategic Focus by Division

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 2026-2028: Strategic Focus by Division A tailored strategy to maximise value extraction from each division, focusing on synergies, new product releases and geog

  8. Slide 8: MedTech: Dedicated Sales Effort into Bioprocessing

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx MedTech: Dedicated Sales Effort into Bioprocessing Commercial synergies and new products drive the core hospital business, while a dedicated sales structure tar

  9. Slide 9: Transfusion Medicine: Building a Global Platform

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Transfusion Medicine: Building a Global Platform Scaling a global transfusion medicine platform in a €1bn addressable market: share recovery in collection and n

  10. Slide 10: Safety: New Products and New Markets Fueling Further Growth

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Safety: New Products and New Markets Fueling Further Growth After three years of consistent growth, Safety keeps expanding: an improved portfolio and a wider ge

  11. Slide 11: Life Sciences: Scaling a Premium Filtration Platform

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Life Sciences: Scaling a Premium Filtration Platform Life Sciences is scaling through wider distribution, a completed filtration portfolio and direct qualificat

  12. Slide 12: Energy & Mobility: Stabilised Base, New Growth Engines

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Energy & Mobility: Stabilised Base, New Growth Engines After years of combustion engine-driven erosion, FY2026 marked a rebound in traditional fuel orders: US r

  13. Slide 13: Margin Expansion: 100 bps driven by organic growth

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Margin Expansion: 100 bps driven by organic growth Further 100bps of margin expansion by 2028, led by pricing and operating leverage ~26% +100 BPS EBITDA MARGIN

  14. Slide 14: Deleverage Path: 1x Target Leverage Ratio by 2028

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Deleverage Path: 1x Target Leverage Ratio by 2028 GVS to continue on its consistent deleveraging path towards a lean, M&A-ready capital structure, supported by

  15. Slide 15: Road to 2030: Growth Engines Beyond the Plan

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Road to 2030: Growth Engines Beyond the Plan 2030 Growth Engines The Bioprocessing Play The Humanoid Robot Frontier In MedTech and Life Sciences In Mobility The

  16. Slide 16: Disclaimer

    ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Disclaimer Pursuant to art. 154-bis, paragraph 2, of the Italian Unified Financial Act of February 24, 1998, the executive in charge of preparing the corporate

GVS — Investor Presentation (September 2026) on 6ix